Key result
Prompt heart failure therapy mitigates and may prevent cancer therapy cardiotoxicity in multidisciplinary cardio-oncology care.
Why the study?
Unique cardiovascular toxicities from modern cancer therapies are increasingly recognized, requiring collaborative cardio-oncology care to manage cardiotoxicity and long-term cardiovascular risk in cancer survivors.
Modern cancer therapy carries cardiovascular risks that require collaborative cardio-oncology management using advanced imaging, biomarkers, and prompt heart failure therapy.
No takes yet. Share an insight, caveat, or question.
Multidisciplinary cardio-oncology care may improve management of therapy-related cardiotoxicity; leaves open optimal prevention and surveillance strategies pending prospective trials.
Johnson et al. (2015) conducted a review in Cancer therapy-induced cardiotoxicity. Cancer therapy was evaluated. Cancer therapy-induced cardiotoxicity responds to prompt heart failure medical treatment, which may also prevent cardiotoxicity, highlighting the need for collaborative cardio-oncology care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: